Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The… Read more »
xCures and BioSpark partner to boost Real World Oncology Data offerings
New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes. xCures, Inc. and BioSpark, Inc. are proud to announce their strategic partnership to harmonize and commercialize a joint oncology Real World Data (RWD) offering. The partnership unlocks new insights into the treatment and… Read more »
TARGET: Cancer Podcast to be hosted by media personality Dr. Sanjay Juneja – TheOncDoc
Oncologist and cancer educator Dr. Sanjay Juneja will host xCures’ informative podcast on cancer and technology February 17, 2022 – Oakland, CA. – xCures, a direct-to-patient, and direct-to-physician oncology platform, is proud to announce Sanjay Juneja, MD, as the host to their TARGET: Cancer podcast. Dr. Sanjay Juneja is a leading oncologist… Read more »
xCures Webinar: Implications of new FDA draft guidance on real-world data explained
TORONTO (PRWEB) DECEMBER 01, 2021 The FDA has issued two new draft guidance documents on the use and structure of real-world data in regulatory decision-making. While real-world data has been around for many years, in this webinar the xCures speakers will recap the guidance and discuss what this means for the… Read more »
xCures presents the results of their oncology platform at the 2021 SNO Annual Meeting
xCures’ poster at the SNO meeting will show results from their XCELSIOR platform of real-world datasets and clinical outcomes in CNS cancer patients. Today, xCures announced their poster presentation at the 26th Annual Meeting of the Society for Neuro-Oncology, held from the 18th to the 21st of November. The Society… Read more »
xCures hosts xDECIDE webinars
xCures is inviting the oncology community to register for a 25-minute webinar introducing a new clinical decision support tool: xDECIDE. Oncology providers now have access to a toolkit that offers tailored recommendations for treatment options and personalized patient health summaries. To accompany the launch of the platform, Dr. Juneja discusses… Read more »
xCures launches xDECIDE to help oncologists find better treatment options for their patients
Portal helps oncologists find the most recent and relevant therapeutic options for advanced cancer patients so they can focus on treatment evaluation xCures announced today the release of xDECIDE, the latest in the company’s suite of tools to empower oncologists and their teams to identify the most suitable, personalized treatment… Read more »
Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCures
First-of-its-kind consortium enables cancer patients to receive anticancer vaccine therapy through compassionate use. The Jaime Leandro Foundation for Therapeutic Cancer Vaccines (JLF) and partners announce the treatment of the first cancer patient with a personalized neoantigen vaccine through a self-pay compassionate use program. JLF is a 501(c)3 non-profit organization whose… Read more »
